VYNE Therapeutics (VYNE) to Release Quarterly Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNE) is expected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect VYNE Therapeutics to post earnings of ($0.20) per share and revenue of $0.1750 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 12:30 PM ET.

VYNE Therapeutics Price Performance

Shares of VYNE Therapeutics stock opened at $0.59 on Thursday. VYNE Therapeutics has a 1-year low of $0.28 and a 1-year high of $2.75. The company has a market capitalization of $19.51 million, a PE ratio of -0.75 and a beta of 2.02. The business has a 50-day moving average of $0.57 and a 200-day moving average of $0.43.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on VYNE. Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen upgraded VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $4.50.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors have recently made changes to their positions in VYNE. Anson Funds Management LP bought a new stake in VYNE Therapeutics in the 4th quarter valued at about $739,000. Nantahala Capital Management LLC acquired a new position in shares of VYNE Therapeutics during the fourth quarter worth approximately $580,000. KVP Capital Advisors LP acquired a new position in shares of VYNE Therapeutics during the fourth quarter worth approximately $290,000. Shay Capital LLC bought a new position in VYNE Therapeutics in the 3rd quarter worth approximately $165,000. Finally, Adage Capital Partners GP L.L.C. increased its position in VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after acquiring an additional 300,000 shares during the period. 83.78% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.